![](https://investorshub.advfn.com/uicon/81806.png?cb=1635633872)
Tuesday, March 25, 2008 6:46:51 PM
(RTTNews) - Altus Pharmaceuticals Inc. (ALTU) on Tuesday reported fourth-quarter net income of $5.47 million from last year's net loss of $14.38 million a year ago. Net income attributable to common stockholders was $5.41 million, compared to net loss of $14.48 million last year. Net income attributable to common stockholders per share was $0.16, compared to net loss per share of $0.63.
Total revenue for the quarter soared to $26.77 million from $1.14 million in the comparable quarter of last year, primarily due to its former ALTU-238 collaboration agreement with Genentech Inc. (DNA), which was terminated effective December 31, 2007. Included in the fourth quarter revenue was $25.1 million associated with the ALTU-238 agreement.
Looking ahead, the firm expects net cash used in operating activities to be between $85 million and $95 million in 2008. This is based on its current operating plans, expected timing and cost of the Trizytek Phase 3 efficacy and safety trials, the ALTU-238 Phase 1c trial, and the ALTU-237 Phase 1 clinical trial and other product development programs.
Among other programs, Altus noted that the Trizytek NDA submission remains on track for first-half of 2009. It reiterated its plans to conduct the Phase 1c trial for ALTU-238, and also plans to report data from the Phase 1 trial of ALTU-237 in hyperoxaluria during the second quarter of 2008.
Recent ALTU News
- Altitude Acquisition Corp. Announces Liquidation of Trust Account • GlobeNewswire Inc. • 03/12/2024 09:33:09 PM
- Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination • GlobeNewswire Inc. • 02/07/2024 09:15:00 PM
- Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination • GlobeNewswire Inc. • 11/03/2023 08:15:00 PM
- Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination • GlobeNewswire Inc. • 10/06/2023 08:10:00 PM
- Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination • GlobeNewswire Inc. • 09/06/2023 08:15:00 PM
- Altitude files Preliminary Merger Proxy Statement for Business Combination with Picard • GlobeNewswire Inc. • 08/14/2023 09:39:17 PM
- Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination • GlobeNewswire Inc. • 08/03/2023 08:15:00 PM
- Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination • GlobeNewswire Inc. • 07/06/2023 12:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM